J Thorac Onco: The efficacy of ostinib monotherapy against CNS metastases in NSCLC patients who have not been treated with radiotherapy

Osimertinib has been reported to be effective in the treatment of central nervous system (CNS) metastases in patients with non-small cell lung cancer ( NSCLC ) with positive activating mutations of epidermal growth factor receptor (EGFR)

The OCEAN study aims to evaluate the efficacy of ostinib's anti-EGFR sensitivity mutation-positive NSCLC patients with non-radiotherapy CNS metastases

The study included two cohort trials and a total of 66 eligible patients were recruited (T790M cohort, n=40; ​​first-line cohort, n=26)

Progression-free survival of 39 patients with brain metastases

The median age of the patients was 69 years and 30% were men

Brain metastasis PFS grouped by EGFR mutation

On day 22 and beyond, the blood trough and the median concentration of cerebrospinal fluid (CSF) of Ostinib were 569 nM and 4.

Blood and CSF concentration of Ostinib and AZ5104

Before treatment, T790M and C797S mutations were detected in the plasma of 83% and 3% of patients, respectively; on day 22, the detection rates of T790M and C797S mutations were 11% and 3%, respectively; when the disease progression was detected, The detection rates of the two mutations were 39% and 22%, respectively

In summary, this study evaluated the efficacy of ostinib anti-EGFR T790M-positive NSCLC patients with CNS metastases that have not been treated with radiotherapy

Original source:

Yamaguchi Hiroyuki, Wakuda Kazushige, Fukuda Minoru et al.